Business Context and Reporting Period
This Form 8-K is filed by Sonus Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) for the reporting period ending May 6, 2008. The filing addresses a critical corporate governance event regarding the company's stock listing status on The NASDAQ Stock Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a current report focused solely on regulatory compliance status.
Material Changes
- Delisting Determination: On May 6, 2008, the company received a determination letter from NASDAQ stating its common stock would be delisted.
- Non-Compliance: The company failed to regain compliance with NASDAQ Marketplace Rule 4450(a)(5), which requires a minimum bid price of $1.00 per share.
- Timeline: The company had a 180-day compliance period starting November 7, 2007, which expired on May 5, 2008, without the company meeting the requirement.
Outlook, Risks, and Management Commentary
- Appeal Process: Management intends to appeal the delisting determination to a NASDAQ Listing Qualifications Panel.
- Trading Status: During the appeal process, the common stock will continue to trade on The Nasdaq Global Market.
- Risk of Delisting: There is no assurance that the NASDAQ Listing Qualifications Panel will grant the request for continued listing.
- Communication: A press release regarding this determination was issued on May 9, 2008, and is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the current status of the appeal with the NASDAQ Listing Qualifications Panel.
- Monitor the stock's bid price to assess if it has recovered to the $1.00 threshold.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the appeal strategy.
- Check for subsequent filings regarding the final decision on the listing status.